Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
A. Chazot, C. Zimberger, M. Feracci, A. Moussa, S. Good, J.-P. Sommadossi, K. ALVAREZ, F. Ferron, B. Canard
This paper reveals the activation pathway of bemnifosbuvir to its active form AT-9010, showing the required enzymes and structural insights into the process.
bioRxiv · Feb 16, 2024 · PreprintBiochemistry
D. L. Hurdiss, P. El Kazzi, L. Bauer, N. Papageorgiou, F. P. Ferron, T. Donselaar, A. L. W. van Vliet, B. Canard, E. Decroly, A. Brancale, T. Zeev-Ben-Mordehai, F. Förster, F. J. M. van Kuppeveld, B. Coutard
This study identifies fluoxetine as an inhibitor of the enterovirus 2C AAA+ ATPase, revealing its mechanism of action through structural and functional analyses.
bioRxiv · Apr 26, 2021Microbiology
H. S. Lo, K. P. Y. Hui, H.-M. Lai, K. S. Khan, S. Kaur, J. Huang, Z. Li, A. K. N. Chan, H. H.-Y. Cheung, K. C. Ng, J. C. W. Ho, Y. W. Chen, B. Ma, P. M.-H. Cheung, D. Shin, , W.-L. Ng
The paper identifies simeprevir as a potent inhibitor of SARS-CoV-2 replication that synergizes with remdesivir in vitro.
ACS Central Science · Apr 15, 2021Peer-reviewedMicrobiology
S. G. Hernandez Tapia, M. Feracci, C. T. De Jesus, P. El-Kazzi, R. Kaci, L. Garlatti, E. Decroly, B. Canard, F. Ferron, K. Alvarez
This paper develops a high-throughput fluorescence polarization assay to screen inhibitors of exoribonucleases from arenaviruses and coronaviruses and validates it with a small compound library.
bioRxiv · Apr 2, 2021 · PreprintBiochemistry
S. C. Bera, M. Seifert, R. Kirchdoerfer, P. van Nies, Y. Wubulikasimu, S. Quack, F. S. Papini, J. J. Arnold, B. Canard, C. E. Cameron, M. Depken, D. Dulin
This study describes the mechanochemical behavior of the SARS-CoV-2 polymerase using magnetic tweezers, revealing three catalytic conformations and a thermal ratchet mechanism for nucleotide incorporation.
bioRxiv · Mar 27, 2021Biophysics
A. Shannon, V. Fattorini, B. Sama, B. Selisko, M. Feracci, C. Falcou, P. Gauffre, P. El Kazzi, E. Decroly, N. Rabah, K. Toulon, C. Eydoux, J.-C. Guillemot, M. Noel, F. Debart, , B. Canard
This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.
bioRxiv · Mar 23, 2021Biochemistry
S. S. Good, J. Westover, K. H. Jung, P. La Colla, G. Collu, A. Moussa, B. Canard, J.-P. Sommadossi
The paper reports that AT-511, a form of AT-527, is a potent in vitro inhibitor of SARS-CoV-2 replication with low cytotoxicity.
bioRxiv · Aug 11, 2020 · PreprintPharmacology & Toxicology
M. Seifert, S. C. Bera, P. van Nies, R. N. Kirchdoerfer, A. Shannon, T.-T.-N. Le, X. Meng, H. Xia, J. M. Wood, L. D. Harris, F. S. Papini, J. J. Arnold, S. C. Almo, T. L. Grove, P.-Y. Shi, , D. Dulin
This study investigates how nucleotide analogs like Remdesivir affect SARS-CoV-2 polymerase activity using single-molecule techniques, revealing backtracking rather than termination and evasion of ddhCTP.
bioRxiv · Aug 6, 2020 · PreprintBiophysics
C. Eydoux, V. Fattorini, A. Shannon, T.-T.-N. Le, B. Didier, B. Canard, J.-C. Guillemot
The paper describes a fluorescence-based high-throughput screening assay for identifying inhibitors of the SARS-CoV RNA synthesis complex using a purified and active replication/transcription complex.
bioRxiv · Jul 7, 2020Biochemistry
A. Shannon, B. Selisko, T.-T.-N. Le, J. Huchting, F. Touret, G. Piorkowski, V. Fattorini, F. Ferron, E. Decroly, C. Meier, B. Coutard, O. Peersen, B. Canard
This study shows Favipiravir inhibits SARS-CoV-2 by targeting its RNA polymerase through chain termination, slowed synthesis, and mutagenesis.
bioRxiv · May 15, 2020 · PreprintBiochemistry
E. Yekwa, C. Aphibanthammakit, X. Carnec, C. Picard, B. Canard, S. Baize, F. Ferron
This paper investigates the RNA exonuclease activity of Arenavirus ExoN, showing it edits genomic RNA and links to genome stability rather than innate immune suppression.
bioRxiv · Feb 13, 2019 · PreprintBiochemistry